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Low‑dose steroids are 
associated with indeterminate 
QuantiFERON‑TB Gold In‑Tube 
assay results in immunocompetent 
children
Kyu Ho Kim1, Ji‑Man Kang1,2 & Jong Gyun Ahn1,2* 
Immunocompromised status can result in indeterminate QuantiFERON‑TB Gold In‑Tube (QFT‑GIT) 
results, but the association of indeterminate results with immunocompetent status in children is 
unknown. Therefore, we aimed to identify factors associated with indeterminate QFT‑GIT results for 
immunocompetent children. We conducted a retrospective chart review of children (aged ≤ 18 years) 
who underwent QFT‑GIT between September 2006 and July 2017 at the Severance Hospital, Seoul, 
South Korea. Of the 2037 QFT‑GIT assays included in the present study, 7.7% yielded indeterminate 
QFT‑GIT results. Multivariable logistic regression analysis identified younger age (OR 0.88; 95% 
CI 0.836–0.927; P < 0.001), elevated white blood cell (WBC) count (OR 1.066; 95% CI 1.020–1.115; 
P = 0.005), decreased albumin levels (OR 0.505; 95% CI 0.316–0.807; P = 0.004), and low‑dose steroid 
therapy (< 1 mg/kg per day of prednisone or equivalent for < 2 weeks) (OR 76.146; 95% CI 8.940–
648.569; P < 0.001) as significant factors influencing indeterminate results. Younger age, high WBC 
count, low albumin levels, and low‑dose steroid therapy were associated with indeterminate QFT‑
GIT results. Low‑dose steroid therapy had the highest OR for the indeterminate results compared to 
other significant risk factors. Our study suggests that screening for steroid doses is important prior to 
performing interferon‑gamma release assays for immunocompetent children.
Tuberculosis (TB) poses a serious threat to public health worldwide as it is the leading cause of death from a 
single infectious disease agent; its mortality rate exceeds that of malaria and HIV/AIDS1. Globally, 10 million 
incident cases of TB occurred in 2018, these included approximately 1 million (11%) TB cases in children under 
the age of 15. However, the mortality rate was higher in children younger than 15 years old, accounting for 14% 
of the total deaths. This is higher than the mortality rate for all incident cases, suggesting poorer diagnosis and 
treatment for children. Additionally, children, especially those under the age of two, are more likely to progress 
from latent TB infection (LTBI) to active TB than  adults2. Therefore, early identification and treatment of LTBI 
in children is an important priority for effectively controlling TB.
Diagnostic tools for LTBI in children include the tuberculin skin test (TST) and interferon-gamma release 
assay (IGRA). Of late, IGRAs are increasingly being used and supported by national guidelines to diagnose  TB3, 4; 
however, their use in children is still limited. There are two major IGRAs available, namely, the QuantiFERON-TB 
(QFT) Gold assay (Cellestis/Qiagen, Carnegie, Australia) and the T-SPOT-TB assay (Oxford Immunotec Ltd., 
Abingdon, United Kingdom). IGRAs measure the levels of interferon-gamma (IFN-γ) produced via sensitized 
T cells in response to stimulation with Mycobacterium tuberculosis-specific antigens, including early-secretory 
antigenic target-6 (ESAT-6) and 10 kDa culture filtrate protein (CFP-10)5. Therefore, IGRAs are not affected by 
the BCG vaccination status or most nontuberculous mycobacterial  infections6. The QFT Gold In-Tube (QFT-
GIT) assay is an enzyme-linked immunosorbent assay (ELISA)-based whole blood test that includes TB7.7 as 
an additional M. tuberculosis-specific antigen. QFT-GIT results are reported as either determinate (positive or 
negative) or indeterminate. Indeterminate results can either occur when there is a high response to the negative 
control or a low response to the positive control. In the clinic, indeterminate QFT-GIT results make it difficult 
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for clinicians to diagnose TB. Immunosuppressed children and adults are at risk of obtaining indeterminate 
QFT-GIT  results7–9. However, even immunocompetent individuals may receive indeterminate QFT-GIT results. 
Additionally, the risk of indeterminate QFT-GIT results for immunocompetent children is currently unknown.
Therefore, the aim of the present study was to identify the factors associated with indeterminate QFT-GIT 
assay results in immunocompetent children.
Results
Baseline characteristics. During the study period, a total of 2707 QFT-GIT assays were performed. A 
total of 670 samples were excluded based on the medical chart review. The exclusion criteria are presented in 
Fig. 1. Therefore, 2037 QFT-GIT assays were included in the present study. Overall, 1881 (92.3%) tests yielded 
determinate results and 156 (7.7%) produced indeterminate results. Of the 1881 determinate results, 178 (9.4%) 
were positive and 1703 (90.6%) were negative. Regarding the 156 indeterminate results, 88 (56.4%) were due to 
positive control failure, 1 (0.6%) due to negative control failure, and 67 (43.0%) had an unknown cause due to 
the absence of detailed results.
Factors associated with indeterminate QFT‑GIT results. Comparisons made between the indeter-
minate and determinate groups are summarized in Table 1. Univariable logistic regression analysis revealed the 
number of individuals with suspected active TB and unknown reason for IGRA test, white blood cell (WBC) 
count, C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), and low-dose systemic steroid use was 
higher in the indeterminate group than that in the determinate group. However, the age at sampling, number of 
individuals screened for LTBI after exposure to TB patient(s), and albumin levels were lower in the indetermi-
nate group than in the determinate group. Moreover, multivariable logistic regression analysis revealed that age 
at sampling (OR 0.88; 95% CI 0.836–0.927; P < 0.001), WBC count (OR 1.066; 95% CI 1.020–1.115; P = 0.005), 
albumin level (OR 0.505; 95% CI 0.316–0.807; P = 0.004), and low-dose systemic steroid use (OR 76.146; 95% CI 
8.940–648.569; P < 0.001) were significantly associated with the attainment of indeterminate QFT-GIT results.
Comparison of indeterminate QFT‑GIT results by age group. To more accurately analyze the rela-
tionship between age and risk of obtaining indeterminate IGRA results, we divided immunocompetent children 
into three age groups: group A (< 4 years old, n = 744), group B (5 to 9 years old, n = 429), and group C (10 to 
18 years old, n = 864).
The proportion of indeterminate results was significantly lower in group C than groups A and B (5.3% vs. 
10.1% at P < 0.001 and 5.3% vs. 8.2% at P = 0.048, respectively) (Fig. 2A). Additionally, the median response to 
the mitogen control phytohemagglutinin (PHA) (censored at 15 IU/mL) was significantly higher in group C 
than that in groups A and B (P = 0.014 and P < 0.001, respectively) (Fig. 2B).
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Figure 2C depicts the median IFN-γ response (censored at 15 IU/mL) to the TB antigen among children 
with a positive QFT-GIT result. The median response to the TB antigen did not differ significantly among the 
three groups.
Comparison of indeterminate QFT‑GIT results with or without low‑dose steroid use. Individu-
als in the low-dose steroid group had a significantly higher proportion of indeterminate results than those in 
the non-steroid group (92.8% vs. 7.0%; P < 0.001) (Fig. 3A). The median response to the mitogen control PHA 
(censored at 15 IU/mL) was significantly lower in the low-dose steroid group than that in the non-steroid group 
(P < 0.001) (Fig. 3B). Since there were no positive QFT-GIT results in the steroid group, we did not compare the 
IFN-γ response to TB antigens in positive samples between the two groups.
Table 1.  Risk of attainment of indeterminate QFT-GIT results in immunocompetent children. IQR 
interquartile range, IGRA interferon gamma release assays, LTBI latent tuberculosis infection, TB tuberculosis, 






(N = 1881) Univariable analysis Multivariable analysis
Median (IQR) or 
N (%)
Median (IQR) or 
N (%) OR (95% Cl) P value OR (95% Cl) P value
Median age at sam-
pling in years (IQR) 5 (2–11) 8 (3–14) 0.951 (0.924–0.979)  < 0.001 0.880 (0.836–0.927)  < 0.001
Male (N [%]) 92 (59.0%) 1020 (54.2%) 0.824 (0.591–1.148) 0.252
Reason for IGRA test (N [%])
Suspected active TB 101 (64.7%) 860 (45.7%) 2.180 (1.551–3.065)  < 0.001 0.618 (0.330–1.157) 0.133
LTBI screening after 
exposure to TB 
patient(s)
14 (9.0%) 683 (36.3%) 0.173 (0.099–0.302)  < 0.001 0.835 (0.097–7.199) 0.870
LTBI screening before 
starting biologics 11 (7.1%) 141 (7.5%) 0.936 (0.495–1.769) 0.839
Unknown 30 (19.2%) 197 (10.5%) 2.035 (1.331–3.112) 0.001
Laboratory findings; median (IQR)
WBC  (103/μL) 10,075 (7260–15,030) 7720 (6120–10,040) 1.127 (1.090–1.165)  < 0.001 1.066 (1.020–1.115) 0.005
Lymphocytes  (103/μL) 1963 (1110–2932) 2065 (1447–2965) 0.940 (0.834–1.059) 0.308
Albumin (g/dL) 3.6 (3.2–4.1) 4.2 (3.8–4.5) 0.313 (0.237–0.414)  < 0.001 0.505 (0.316–0.807) 0.004
CRP (mg/dL) 12.6 (2.2–57.0) 6.2 (1–30.7) 1.008 (1.005–1.011)  < 0.001 1.004 (0.999–1.009) 0.149
ESR (mm/h) 46 (21–85.0) 32 (14–58.0) 1.004 (0.995–1.013)  < 0.001 1.002 (0.994–1.011) 0.589
Low-dose corticoster-
oid use (N [%]) 13 (8.3%) 1 (0.05%)
66.458 (7.657–
576.811)  < 0.001
76.146 (8.940–
648.569)  < 0.001
Figure 2.  (A) Proportion of indeterminate QFT-GIT results in group A (< 4 years old), B (5 to 9 years old), and 
C (10 to 18 years old). (B) IFN-γ response to the mitogen control PHA (censored at 15 IU/mL) according to the 
age group. Red lines indicate the median values. P values were calculated using the Mann–Whitney U test. (C) 
IFN-γ response to the TB antigens (censored at 15 IU/mL) according to age of children with a positive QFT-GIT 
result. The red lines indicate the median values. P values were calculated using the Mann–Whitney U test. QFT-
GIT QuantiFERON-TB Gold In-Tube, PHA phytohemagglutinin, IFN-γ interferon-gamma, TB tuberculosis.
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Discussion
This study focused on the risk of indeterminate QFT-GIT assay results in immunocompetent children. Previous 
studies have reported that an immunocompromised status contributes to indeterminate QFT-GIT results for 
 children7. We found that a younger age, high WBC counts, low albumin levels, and low-dose steroid use were 
significantly associated with indeterminate QFT-GIT results for immunocompetent children.
Even in healthy children, low-dose steroids are prescribed for a variety of anti-inflammatory therapeutic pur-
poses. The effects of these low-dose steroids on IGRA testing in immunocompetent children can be overlooked. 
Our study showed that using low doses of steroids had the highest OR for the indeterminate results compared 
to all the other significant risk factors. Supplementary Table S1 online demonstrates that the median dose and 
duration of steroid use was equivalent to 0.7 mg/kg per day prednisone (IQR 0.7–0.7) and 1 day (IQR 1.0–1.0), 
respectively. In the present study, most cases treated with low-dose steroids were used as adjuvant treatments 
for pneumonia (9/14), dyspnea in asthma (3/14), and acute respiratory distress syndrome (1/14). As a common 
cause of pneumonia, Mycoplasma pneumoniae was found in 4 cases, whereas parainfluenza virus was found in 
1 case, and Streptococcus pneumoniae was found in 1 case. In the remaining three cases, the causative pathogen 
was not determined. Nevertheless, most IGRA tests were performed to screen TB as a differential diagnosis in 
these patients with pneumonia that presented with severe symptoms that did not respond to common antibiotics. 
However, adverse effects of glucocorticoids on the immune system are both dose- and duration-dependent10–13. 
Less than 1 mg/kg per day of prednisone is considered a low-to-moderate dose for  children10. Although even 
low-dose steroids may adversely affect the functioning of the immune system in some individuals, the use of 
the lowest dose of glucocorticoids for the shortest period of time has not been implicated in increasing the risk 
of severe immunosuppression. Therefore, administering killed or attenuated vaccines can proceed normally in 
children receiving low doses of  steroids14–17. Our results suggest that even low doses of steroids can significantly 
impact QFT-GIT results; therefore, prior to QFT-GIT testing, it is important to check whether patients have 
been administered steroids.
The QFT-GIT assay is an in vitro blood test based on the release of IFN-γ by T cells in response to stimula-
tion with TB-specific antigens. Thus, IGRA testing in HIV-infected individuals with a reduced T cell count is 
more likely to result in indeterminate  results18. Glucocorticoids impair a variety of T cell functions; therefore, 
high doses can induce T cell apoptosis, which leads to the inhibition of Th1-derived cytokines, such as IFN-γ, 
interleukin (IL)-2, IL-10, and tumor necrosis factor (TNF)19. In two ex vivo  models19, 20, dexamethasone altered 
QFT-GIT assay results from positive to negative in 30–40% of the subjects. Several studies in adults have reported 
that patients receiving at least one immunosuppressive drug, including steroids, were at an increased risk of 
obtaining indeterminate  results5, 21–24. However, these studies were conducted in adult patients with underlying 
diseases, such as inflammatory bowel disease (IBD) or autoimmune disease, which have been commonly treated 
using steroids. Therefore, it was necessary to interpret the results carefully, as it was possible that the patients’ 
underlying diseases affected their QFT-GIT results. In addition, long-term steroid use is likely responsible for 
the immunosuppression observed in the aforementioned studies. However, our study revealed the effect of 
low-dose steroid use on indeterminate QFT-GIT results; patients with underlying diseases and those receiving 
immunosuppressive treatments were excluded. Our findings suggest that even low-dose steroids can reduce T 
cell function and impact the IGRA response; thus, IGRA tests should be performed prior to the use of steroids 
and in patients that may benefit from its biologics.
The results of the present study correspond with those of earlier studies which reported that young age was 
independently associated with a higher risk of obtaining indeterminate QFT-GIT  results5, 7, 8. In particular, we 
observed that the response to the mitogen control PHA was significantly higher in children older than 10 years 
compared with that in children younger than 10 years old. These findings are supported by previous studies that 
have observed an age-associated increase for IFN-γ concentrations in healthy  children25, 26.
Figure 3.  (A) Proportion of indeterminate QFT-GIT results in the low-dose steroid group and non-steroid 
group. (B) IFN-γ response to mitogen control PHA (censored at 15 IU/mL) in children with and without 
low-dose steroid therapy. The red lines indicate the median values. P values were calculated using the Mann–
Whitney U test. QFT-GIT QuantiFERON-TB Gold In-Tube, IFN-γ interferon-gamma.
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However, there was no difference in the IFN-γ response to TB antigens among the age groups. These findings 
suggest that a younger age does not affect T-lymphocyte release of IFN-γ in response to a TB-specific antigen. 
Interestingly, a previous study reported similar results in that TB antigen-induced IFN-γ responses were signifi-
cantly higher in children than adults and that insufficient IFN-γ production in response to PHA stimulation was 
more common in children than in  adults5. Although it is not clear why this discrepancy occurs, these findings 
suggest that for children, the QFT-GIT assay requires correction for the positive control (Mitogen) according to 
the age group, but a correction is unnecessary for TB antigens.
Regarding the influence of laboratory findings on the QFT-GIT test, our results demonstrated that high 
WBC counts and low albumin levels were significantly associated with indeterminate results. However, since the 
median value for the WBC count falls within the normal range for a child’s age in both the indeterminate and 
determinate groups, and the OR value was not large, the WBC count was considered to have little effect on the 
IGRA test results. In previous studies, hypoalbuminemia was associated with indeterminate QFT-GIT results in 
critically ill adults or patients with  IBD27, 28. Albumin is a well-known negative acute phase reactant because its 
level decreases with inflammation, in which various relevant cytokines, such as IL-1, IL-6, and TNF-α, suppress 
the synthesis of  albumin29, 30. However, since our study was conducted for immunocompetent children with no 
evidence of chronic inflammation, hypoalbuminemia may have affected the IGRA test results. Therefore, further 
research is needed to elucidate the mechanisms underlying the effects of low albumin levels on IGRA testing.
This study had several limitations. First, possible biases may have occurred due to the retrospective and single-
center nature of this study. We attempted to reduce this effect by including a large cohort of immunocompetent 
children in the analysis. Second, we could not evaluate factors external to the patient, such as specimen handling 
and processing. In addition, the age window for children in the determinate and indeterminate groups may be 
too broad to serve as a real representation of the WBC profile that changes significantly between these different 
age groups. Third, since the IFN-γ response to the TB antigen by age group was analyzed among children with 
a positive QFT-GIT result, this resulted in a relatively small group size. Moreover, the IFN-γ concentration was 
censored when the value exceeded 15 IU/mL; subsequently, analyzing such comparisons were limited, especially 
as the results were influenced by the censored data. Additional prospective large-scale studies, including assess-
ing factors external to the patients, are required to resolve these limitations. Nevertheless, our study identified 
factors associated with inconclusive diagnostic test results from conventional TB tests, which highlights the 
contribution of our results given the importance of accurate and timely diagnosis of TB. However, the findings 
from this study should be further verified using other diagnostic methodologies to demonstrate that our results 
are universally applicable across testing systems and not unique to the IGRA-GIT platform.
In conclusion, we identified that 7.7% of immunocompetent children produced indeterminate IGRA results 
and that factors, including younger age, high WBC count, low albumin levels, and low-dose steroid use, were 
associated with the attainment of indeterminate QFT-GIT results. Notably, the highest OR was observed for 
low-dose steroid use. Therefore, our study highlights the importance of screening for steroid use, even in low 
doses, prior to performing IGRAs for immunocompetent children.
Materials and methods
Study population. We retrospectively reviewed the medical charts of 2707 children, aged ≤ 18 years, who 
underwent QFT-GIT between September 2006 and July 2017 at Severance Hospital, Seoul, South Korea. Elec-
tronic health record (EHRs) were searched for all orders of the QFT-GIT assay conducted during the study 
period. Data extracted from the EHRs included the patient identification (ID) number, demographic varia-
bles, such as age and gender at sampling, and QFT-GIT results. Using the patient ID number, their charts were 
reviewed to indicate the initial reason for conducting the QFT-GIT assay, relevant laboratory data, use of sys-
temic steroids or immunosuppressive agents, and immune status. Immunocompromised patients or individuals 
with no information regarding immune status were excluded from the present study. Additionally, the following 
exclusion criteria were used: patients with (1) known primary immune deficiencies; (2) malignancies and receiv-
ing chemotherapy or immunosuppressive therapy; (3) hematopoietic stem cell or solid organ transplants; (4) 
inflammatory disorders and receiving systemic immunosuppressive treatment, including glucocorticoid dose 
equivalent to prednisone ≥ 1 mg/kg per day or long-term use (2 weeks or more) regardless of dose, as well as 
azathioprine, methotrexate, and cyclophosphamide; (5) asplenia; (6) HIV; and (7) unknown immune status. 
Immunocompetent children were defined as patients without the immunocompromised factors as described 
above. The charts of patients receiving low doses of steroids (< 1 mg/kg per day of prednisone) for less than 
2 weeks were carefully reviewed and included in the study, unless they fulfilled one or more exclusion criteria. 
The demographic and clinical characteristics of children receiving low-dose systemic steroids included in the 
present study are presented in Supplementary Table S1.
QFT‑GIT assay. QFT-GIT assays were performed and interpreted according to the manufacturer’s instruc-
tions in a fully accredited diagnostic laboratory in Severance Hospital. Briefly, whole blood was collected in 3 
test tubes [negative control antigen (Nil), positive control antigen (Mitogen), and TB-specific antigens (ESAT-6, 
CFP-10, and TB7.7)] and incubated at 37 °C for 16–24 h. After centrifugation, IFN-γ production was meas-
ured via enzyme-linked immunosorbent assay (ELISA). Data were converted to IU/mL of IFN-γ. Indeterminate 
results were defined as per manufacturer’s instructions, i.e., failure of the positive control (Mitogen-Nil < 0.5 IU/
mL) or negative control (Nil > 8 IU/mL).
Statistical analysis. The data were analyzed using SAS software, Version 9.4 of the SAS System for Unix. 
Copyright 2020 SAS INSTITUTE INC. SAS and all other SAS INSTITUTE INC. product or service names are 
registered trademarks or trademarks of SAS INSTITUTE INC., Cary, NC, USA. Descriptive statistics were used 
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to express continuous variables using median and interquartile range (IQR) and categorical variables using fre-
quency and percentage. The chi-squared test (Fisher’s exact test) and Mann–Whitney U test were performed to 
compare categorical and continuous variables, respectively. Potential factors associated with the attainment of 
indeterminate results were identified using univariable logistic regression analysis. Multivariable logistic regres-
sion analysis was used to generate ORs and 95% CIs using significant variables (P < 0.05) identified in the uni-
variable model and suggested potential risk factors. The Mann–Whitney U test was used to compare median 
TB antigen/mitogen values between two age groups. Additionally, the Kruskal–Wallis test was used to make 
comparisons among the three age groups. P values less than 0.05 were considered statistically significant.
Ethics approval and consent to participate. This study was performed in accordance with institutional 
and national regulations and approved by the institutional review board (IRB) of the Yonsei University Health 
System (IRB approval number 4-2020-0208) that waived requirements for informed consent due to the retro-
spective nature of the study.
Data availability
The datasets used and/or analyzed in the present study are available from the corresponding author upon rea-
sonable request.
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